George G Bastakis1, Dimitris Dimopoulos1, Anastasios Stavrakakis1, George Pappas2. 1. Ophthalmology Clinic, Medical Retina & Vitreoretinal Surgery Department, Venizeleio Hospital of Crete, Knossos avenue 44, Crete, 71409,, Heraklion, Greece. 2. Ophthalmology Clinic, Medical Retina & Vitreoretinal Surgery Department, Venizeleio Hospital of Crete, Knossos avenue 44, Crete, 71409,, Heraklion, Greece. gpappasresearch@gmail.com.
Abstract
PURPOSE: To evaluate the efficacy and duration of action of an intravitreal (dexamethasone (Ozurdex)) implant in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema (DMO). METHODS: We retrospectively analysed the records for 18 eyes that had or had not been vitrectomised but required an intravitreal dexamethasone implant for DMO after a poor response to anti-vascular endothelial growth factor. Optical coherence tomography and visual acuity (VA) examinations were performed before and 1, 3 and 6 months after implantation. The six months following implantation constituted one treatment round; up to three rounds were studied. RESULTS: Ten of 18 eyes had undergone vitrectomy. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were significantly improved by months 1-3 after implantation of the Ozurdex device in all rounds of treatment. The BCVA and CMT deteriorated gradually after month 3 through to month 6 post implantation. There were no statistically significant differences between the vitrectomised and non-vitrectomised groups at any time point. When the implantation interval was <6 weeks from the end of each treatment round, the improvement in BCVA and CMT was obvious even after 18 months of treatment. CONCLUSIONS: Vitrectomy did not have a negative effect on the duration of action or efficacy of the Ozurdex implant in patients with persistent DMO. The implant started working from the first month after implantation regardless of whether vitrectomy had or had not been performed. The maximum functional and anatomic improvement was achieved in the first 3 months post implantation in all treatment rounds.
PURPOSE: To evaluate the efficacy and duration of action of an intravitreal (dexamethasone (Ozurdex)) implant in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema (DMO). METHODS: We retrospectively analysed the records for 18 eyes that had or had not been vitrectomised but required an intravitreal dexamethasone implant for DMO after a poor response to anti-vascular endothelial growth factor. Optical coherence tomography and visual acuity (VA) examinations were performed before and 1, 3 and 6 months after implantation. The six months following implantation constituted one treatment round; up to three rounds were studied. RESULTS: Ten of 18 eyes had undergone vitrectomy. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were significantly improved by months 1-3 after implantation of the Ozurdex device in all rounds of treatment. The BCVA and CMT deteriorated gradually after month 3 through to month 6 post implantation. There were no statistically significant differences between the vitrectomised and non-vitrectomised groups at any time point. When the implantation interval was <6 weeks from the end of each treatment round, the improvement in BCVA and CMT was obvious even after 18 months of treatment. CONCLUSIONS: Vitrectomy did not have a negative effect on the duration of action or efficacy of the Ozurdex implant in patients with persistent DMO. The implant started working from the first month after implantation regardless of whether vitrectomy had or had not been performed. The maximum functional and anatomic improvement was achieved in the first 3 months post implantation in all treatment rounds.
Authors: Paul M Beer; Sophie J Bakri; Ravinder J Singh; Weiguo Liu; George B Peters; Michael Miller Journal: Ophthalmology Date: 2003-04 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Susan S Lee; Corine Ghosn; Zhiling Yu; Leandro C Zacharias; Henry Kao; Carmine Lanni; Natania Abdelfattah; Baruch Kuppermann; Karl G Csaky; David Z D'Argenio; James A Burke; Patrick M Hughes; Michael R Robinson Journal: Invest Ophthalmol Vis Sci Date: 2009-12-17 Impact factor: 4.799
Authors: Hüseyin Baran Özdemir; Murat Hasanreisoğlu; Murat Yüksel; Mestan Ertop; Gökhan Gürelik; Şengül Özdek Journal: Turk J Ophthalmol Date: 2019-12-31